drugset / Trial / NCT02669849

Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

NCT02669849 ↗

Phase 2/3 Terminated 70 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the efficacy and safety of VX-210 in subjects with Acute Traumatic Cervical Spinal Cord Injury. Secondary objectives include the specific evaluation of the effects of VX-210 on neurological recovery and daily function after spinal cord injury.

Timeline

Start
2016-07
Primary completion
2018-11
Completion
2018-11

Outcome

Missed primary endpoint

registry analysis (superiority test); Placebo vs VX-210 9 mg; p = 0.7519 NCT02669849 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject VX-210 Unknown — —

Indications